Skip to main content
Log in

Orbicular synkinesis after facial paralysis: Treatment with botulinum toxin

  • Published:
Documenta Ophthalmologica Aims and scope Submit manuscript

Abstract

Involuntary lid closure not rarely accompanies aberrant regeneration of nerve fibers after different types of facial paralysis. 23 patients with such synkinesis were treated with botulinum toxin injections into the orbicularis oculi muscle. After periocular injections all patients showed much improvement: a period of, on the average, 13 symptom-free weeks was followed by a period of minimal symptoms. There were only minor complications. Whenever repeated treatment is necessary, botulinum toxin proves to be an effective therapy for involuntary lid closure after defective healing following facial paralysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Stennert E. Das Autoparalytische Syndrom - ein Leitsymptom der postparetischen Fazialisfunktion. Arch Otorhinolaryngol 1982; 236: 97–114.

    PubMed  Google Scholar 

  2. Roggenkämper P. Blepharospasmus-Behandlung mit Botulinus-Toxin (Verlaufsbeobachtungen). Klin Monatsbl Augenheilk 1986; 189: 283–285

    Google Scholar 

  3. Scott AB. Botulinum toxin therapy of eye muscle disorders. Safety and effectiveness (Ophthalmic Procedures Assessment, American Academy of Ophthalmology). Ophthalmology 1989; Instrument and Book Issue

  4. Dengler R, Konstanzer A, Ceballos-Baumann AO. Lokale Therapie mit Botulinum Toxin A bei fokalen Dystonien. Akt Neurol 1990; 17: 133–138

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roggenkämper, P., Laskawi, R., Damenz, W. et al. Orbicular synkinesis after facial paralysis: Treatment with botulinum toxin. Doc Ophthalmol 86, 395–402 (1994). https://doi.org/10.1007/BF01204598

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01204598

Key words

Navigation